[Disability Progression in SPMS Despite Therapeutic Intervention: Current Status and Perspectives of Treatment with Disease-Modifying Drugs].

Abstract

Currently, siponimod is the only disease-modifying drugs (DMDs) with proven efficacy and safety in clinical trials for secondary progressive multiple sclerosis (SPMS). However, the efficacy of siponimod in preventing disability progression is insufficient and it has not yet been able to deter disability progression. Therefore, it is considered necessary to use DMDs with a high relapse-preventive effect at a relatively early stage of SPMS, while disease activity remains evident. Bruton's tyrosine kinase inhibitors have the potential to prevent progression of all MS disease types and are expected to be the cornerstone of the next generation of treatment. The results of these clinical trials are awaited.

• Authors: Takashi Ohashi
• Journal: Brain and nerve = Shinkei kenkyu no shinpo (Brain Nerve) Vol. 74 Issue 5 Pg. 505-509 (May 2022) ISSN: 1881-6096 [Print] Japan
• PMID: 35589639 (Publication Type: Journal Article)

Topics

• Disabled Persons
• Disease Progression
• Humans
• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive (drug therapy)